Lanitop®

Metildigoxin, the active ingredient in Lanitop, is a cardiac glycoside presented as an oral tablet for oral use. It is employed to increase cardiac contractility in patients with certain forms of heart failure and to aid rate control in atrial arrhythmias. GNH USA supplies Lanitop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Metildigoxin is used in cardiac conditions that benefit from enhanced myocardial contractility and rhythm control.

Congestive heart failure: improves ventricular pumping efficiency and reduces symptoms of fluid overload. Atrial fibrillation: helps control ventricular rate by increasing vagal tone. Atrial flutter: assists in rate control and may aid conversion to sinus rhythm.

Adverse reactions may occur with Metildigoxin therapy.

Common Side Effects: - Nausea or vomiting - Diarrhea - Blurred vision or color disturbances - Fatigue or weakness - Headache - Dizziness

Serious or Rare Side Effects: - Life‑threatening arrhythmias (e.g., ventricular tachycardia) - Severe bradycardia or heart block - Hyperkalemia - Visual halos (yellow‑green) - Allergic skin reactions - Confusion or hallucinations

When prescribing Metildigoxin, clinicians should consider several safety factors.

Renal impairment: dose may need adjustment and serum levels should be monitored. Electrolyte imbalance: monitor potassium and magnesium closely. Thyroid disease: increased sensitivity may occur. Elderly patients: higher risk of toxicity; start with lower doses. Therapeutic drug monitoring: regular serum Metildigoxin concentrations are recommended. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metildigoxin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Amiodarone: markedly raises serum Metildigoxin levels. - Quinidine: increases concentration and toxicity risk. - Verapamil: enhances cardiac effects and may precipitate arrhythmias.

Moderate Interactions (Monitor Closely): - Loop or thiazide diuretics: may cause electrolyte disturbances that potentiate toxicity. - Beta‑blockers: additive bradycardic effect. - ACE inhibitors: may affect renal function and electrolyte balance. - NSAIDs: can reduce renal clearance of Metildigoxin. - SSRIs: potential for QT‑interval prolongation.